Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Akcea Therapeutics, Inc.    AKCA

AKCEA THERAPEUTICS, INC.

(AKCA)
  Report
SummaryQuotesChartsNewsRatingsCompanyFinancials 
Strengths

No significant strength

Weaknesses
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart
Sector Pharmaceuticals - NEC
1st jan.Capitalisation (M$)Investor Rating
AKCEA THERAPEUTICS, INC.7.26%1 849
-
JOHNSON & JOHNSON-0.82%379 086
ROCHE HOLDING AG-3.66%285 972
PFIZER, INC.3.21%206 939
NOVARTIS AG-11.80%203 829
MERCK & CO., INC.-12.19%202 049
ABBVIE INC.18.47%185 181
NOVO NORDISK A/S8.43%155 954
BRISTOL-MYERS SQUIBB COMPAN..-2.79%142 477
ASTRAZENECA PLC2.60%135 908
ELI LILLY AND COMPANY10.82%133 666
AMGEN INC.-7.89%130 877
SANOFI-5.48%127 996
GLAXOSMITHKLINE PLC-22.99%91 797
CHUGAI PHARMACEUTICAL CO., ..42.95%76 661
DAIICHI SANKYO COMPANY, LIM..56.60%72 682
More Results
Financials (USD)
Sales 2019 489 M - -
Net income 2019 40,8 M - -
Net cash 2019 448 M - -
P/E ratio 2019 59,2x
Yield 2019 -
Capitalization 1 849 M 1 849 M -
EV / Sales 2018 37,6x
EV / Sales 2019 2,34x
Nbr of Employees 294
Free-Float 17,2%
Notations Surperformance©
  Help  
Fundamental ratings
Overall rating
Trading Rating -
Investor Rating -
Growth (Revenue) -
Valuation -
Finances -
Profitability -
Earnings quality
Business Predictability -
P/E ratio -
Potential -
Yield -
Consensus -
7 days EPS revision
4 months EPS revision
1 year EPS revision
4 months Revenue revision
1 year Revenue revision